International Liver Congress
International Liver Congress
April 14, 2018
4 min watch

Women on HRT, birth control safely, effectively treated HCV with Zepatier

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

PARIS — Though some direct-acting antivirals conflict with the administration of hormone replacement therapy or oral contraceptives, a recent study showed safety and efficacy with Zepatier, according to a our exclusive interview with Christophe Hezode, MD, at the International Liver Congress 2018.

“It’s very important to check drug-drug interaction before starting treatment and we know that it’s very important to know that with ... Zepatier there is absolutely no drug-drug interactions between [oral contraceptive products (OCP)] and [hormone replacement therapy (HRT)],” Hezode of Hopital Henri Mondor, Paris, France, told Healio Gastroenterology and Liver Disease.

Hezode and colleagues pooled data from 12 clinical trials on Zepatier (elbasvir/grazoprevir, Merck) and found 1,022 female patients, 82 (7.9%) of whom concurrently took HRT or OCP.

They found that sustained virologic response was similar in women who took HRT or OCP (SVR12 of 95.1%) and those who did not (SVR12 of 96.3%). Serious adverse events did not occur in any women on HRT or OCP and just three women (0.3%) not taking these medications. Due to increased alanine minotransferase or aspartate aminotransferase levels, one woman (1.2%) on HRT/OCP and seven women (0.7%) not on HRT/OCP discontinued treatment.

“You can easily treat ... women with OCP or HRT with elbasvir and grazoprevir. It's very safe, there is no drug-drug interaction, there is no ALT elevation,” Hezode said.

For more information:

Hezode C, et al. THU-301. Presented at: International Liver Congress; Apr. 11-15, 2018; Paris, France.

Disclosure: Hezode reports financial relationships with AbbVie, BristolMyers Squibb, Gilead, Janssen, and Merck.